Nektar Therapeutics has filed a patent for multi-arm polymer conjugates of Toll-Like Receptor agonists, specifically TLR 7/8 agonists, for use in cancer treatment. The conjugates involve a unique structure and method of administration, potentially offering new therapeutic options. GlobalData’s report on Nektar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Nektar Therapeutics - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nektar Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Nektar Therapeutics's grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

Polymer conjugates of tlr 7/8 agonists for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Nektar Therapeutics

A patent application (Publication Number: US20230372500A1) discloses a novel conjugate for potential use in cancer treatment. The conjugate consists of a Toll-like receptor (TLR) 7/8 agonist covalently attached to a multi-arm, water-soluble, non-peptidic polymer via a linkage-containing spacer moiety. The TLR 7/8 agonist can be a small molecule and is attached at the terminus of one or more arms of the polymer. The structure of the conjugate is defined by a specific formula, with variations in the number of polymer arms, spacer moieties, and TLR 7/8 agonists. The patent also covers methods of treatment involving the administration of the conjugate, either alone or in combination with other agents, for cancer therapy.

Furthermore, the patent application includes claims related to the composition, method of treatment, and administration protocols using the conjugate for cancer treatment. The conjugate can be combined with a long-acting interleukin-2 receptor beta (IL-2Rß)-biased agonist for enhanced therapeutic effects. Various administration methods, including local and parenteral routes, are described, along with specific dosing regimens and treatment cycles. The patent application emphasizes the potential use of the conjugate in solid cancers, such as breast, colon, and lung cancer, and highlights the importance of achieving an abscopal effect and improved survival rates in preclinical models. Overall, the patent application presents a promising approach to cancer therapy by leveraging the unique properties of the conjugate and its combination with other immunomodulatory agents for enhanced efficacy in treating cancer.

To know more about GlobalData’s detailed insights on Nektar Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies